Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
Mallinckrodt
Colorcon
Deloitte
Farmers Insurance
Argus Health
Moodys
Citi

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,361,649

« Back to Dashboard

Which drugs does patent 7,361,649 protect, and when does it expire?

Patent 7,361,649 protects CORLANOR and is included in one NDA.

This patent has forty-six patent family members in forty-two countries.
Summary for Patent: 7,361,649
Title:.beta.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Abstract: A .beta.-Crystalline form of ivabradine of formula (I): ##STR00001## characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Inventor(s): Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR)
Assignee: Les Laboratoires Servier (Courbevoie Cedex, FR)
Application Number:11/358,954
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,361,649

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-001 Apr 15, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE ➤ Try a Free Trial
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-002 Apr 15, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,361,649

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 01985Feb 28, 2005

Non-Orange Book US Patents Family Members for Patent 7,361,649

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,879,842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,361,649

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1907 ➤ Try a Free Trial
Argentina 053147 ➤ Try a Free Trial
Austria 407926 ➤ Try a Free Trial
Australia 2006200856 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Argus Health
Deloitte
UBS
Teva
Chinese Patent Office
Moodys
Cerilliant
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.